Telesis Bio Releases BioXp® Select Kits to Enable DNA Amplification and Scale-up
New Releases Extend the BioXp® Select Product Line, Further Expanding the Utility, Speed, and Impact…
ISP
Telesis Bio Releases BioXp® Select Kits to Enable DNA Amplification and Scale-up
New Releases Extend the BioXp® Select Product Line, Further Expanding the Utility, Speed, and Impact…
Nkarta Announces Departure of Chief Financial & Business Officer
Clinical updates on track for NKX101 in first half of 2023 and NKX019 in full…
IMUNON Reports 2022 Financial Results and Provides Business Update
Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J., March 30, 2023 (GLOBE…
Trobix Bio Raises $3 Million from Chartered Group to Advance Precision Microbiome Oncology Therapeutics
Adi Elkeles CEO of Trobix Bio Netanya, Israel, March 30, 2023 – Trobix Bio, a…
CRISPR Therapeutics Announces Departure of Board Member
ZUG, Switzerland and BOSTON, March 29, 2023 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP), a…
CRISPR Therapeutics Announces Departure of Board Member
ZUG, Switzerland and BOSTON, March 29, 2023 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP), a…
Inozyme Pharma Reports Full Year 2022 Financial Results and Provides Business Highlights
– Founding CEO, Axel Bolte, MSc, MBA, to retire; Douglas A. Treco, Ph.D., to succeed…
Sana Biotechnology Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates
Announced SC291 IND clearance with goal to report initial clinical data this year Expect to…
Sana Biotechnology Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates
Announced SC291 IND clearance with goal to report initial clinical data this year Expect to…
CancerVax Files Non-Provisional Patent for Universal Cancer Vaccine
The Company’s patent application describes how it plans to leverage cutting-edge CRISPR and mRNA technologies…
CancerVax Files Non-Provisional Patent for Universal Cancer Vaccine
The Company’s patent application describes how it plans to leverage cutting-edge CRISPR and mRNA technologies…
Nkarta Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights
Clinical updates on track for NKX101 in first half of 2023 and NKX019 in full…
Nkarta Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights
Clinical updates on track for NKX101 in first half of 2023 and NKX019 in full…
iOmx Therapeutics to Present Target Discovery Platform Myeloid iOTarg™ and New Data on SIK Checkpoint Inhibitor OMX-0407 at AACR 2023
Discovery of novel immune checkpoints in the tumor microenvironment with iOTarg™ screening platform Predictive biomarker…
CRISPR Therapeutics to Present at the American Association for Cancer Research 2023 Annual Meeting
ZUG, Switzerland and BOSTON, March 14, 2023 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical…
CRISPR Therapeutics Announces Transition of Chief Financial Officer
ZUG, Switzerland and BOSTON, March 13, 2023 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP), a…
Editas Medicine Strengthens Executive Leadership Team with Appointment of Linea Aspesi as Chief People Officer
Linea Aspesi Linea Aspesi, Executive Vice President and Chief People Officer, Editas Medicine CAMBRIDGE, Mass.,…
Metagenomi Recognized as One of World’s Most Innovative Companies by Fast Company
EMERYVILLE, Calif.–(BUSINESS WIRE)–Metagenomi, a genetic medicines company with a versatile portfolio of wholly owned, next-generation…
IMUNON CEO Issues Letter to Shareholders
Reviews 2022 accomplishments; sets forth 2023 milestones and long-term vision LAWRENCEVILLE, N.J., March 01, 2023…